Improving the Quality of Two Lives by Treating Obesity.

Nagy N, Kleinová P, Péč MJ, Samoš M, Dedinská I

Reports (MDPI)3 Jun 2025

PMID40710876PMCIDPMC12196773DOI10.3390/reports8020085PepBankPUB-40710876

Summary

Background and Clinical Significance: Kidney transplantation remains the most effective method of renal replacement therapy. Living donor transplantation offers several advantages-reduced cardiovascular risk, better graft survival, and preemptive intervention. However, donor obesity is a growing concern, as it is usually associated with perioperative and long-term complications, which can affect donor eligibility. Bariatric surgery is a standard recommendation for patients with a BMI over 35 kg/m². There are limited data on the use of pharmacological agents for weight reduction in kidney donors. This case presents a successful conservative treatment with GLP-1 receptor agonist in an obese woman wishing to donate a kidney to her son. Case Presentation: We are presenting the case of a 63-year-old woman with grade II obesity who was initially denied being a kidney donor to her son because of her weight. Under these circumstances, she underwent comprehensive lifestyle modification in the cardio-obesitology clinic (caloric restriction, physical activity, and pharmacological treatment with liraglutide). During the 3-month follow-up, she decreased her BMI to 33.4 kg/m², and subsequent examinations confirmed no surgical contraindications to donating a kidney. Despite hematuria, biopsy and genetic testing revealed a benign carrier condition of Alport syndrome, which, without proteinuria or renal impairment, allowed successful kidney donation. Conclusions: This case demonstrates that conservative pharmacological treatment for body weight reduction with GLP-1 receptor agonists may be an alternative to bariatric surgery for selected obese kidney donor candidates. The presented case highlights the importance of a multidisciplinary and personalized approach.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesEfficacy outcome
In one 63-year-old woman with grade II obesity, liraglutide alongside caloric restriction and physical activity was followed by BMI of 33.4 kg/m<sup>2</sup> at 3-month follow-up.
In plain wordsIn one potential kidney donor with obesity, liraglutide treatment alongside lifestyle changes was followed by lower BMI at 3 months.
Peptide
Liraglutide
Outcome
Decreasebody mass index
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
BMI
33.4 kg/m<sup>2</sup>
3-month follow-up
Source sentences
Summary
During the 3-month follow-up, she decreased her BMI to 33.4 kg/m², and subsequent examinations confirmed no surgical contraindications to donating a kidney.
2 context sentences(design, population, supporting numbers)
Summary · context
We are presenting the case of a 63-year-old woman with grade II obesity who was initially denied being a kidney donor to her son because of her weight.
Summary · context
Under these circumstances, she underwent comprehensive lifestyle modification in the cardio-obesitology clinic (caloric restriction, physical activity, and pharmacological treatment with liraglutide).
Show in the study text Report a problemFND-4071087601
02HumanCase report or seriesOther
In one potential kidney donor with grade II obesity, subsequent examinations after liraglutide treatment alongside lifestyle modification found no surgical contraindications to kidney donation.
In plain wordsIn one potential kidney donor with obesity, later examinations found no surgical barrier to kidney donation after liraglutide treatment and lifestyle changes.
Peptide
Liraglutide
Outcome
Not applicablesurgical contraindications to kidney donation
Study
n = 1
Outcome group
Overall treatment effect · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
During the 3-month follow-up, she decreased her BMI to 33.4 kg/m², and subsequent examinations confirmed no surgical contraindications to donating a kidney.
2 context sentences(design, population, supporting numbers)
Summary · context
We are presenting the case of a 63-year-old woman with grade II obesity who was initially denied being a kidney donor to her son because of her weight.
Summary · context
Under these circumstances, she underwent comprehensive lifestyle modification in the cardio-obesitology clinic (caloric restriction, physical activity, and pharmacological treatment with liraglutide).
Show in the study text Report a problemFND-4071087602
03HumanCase report or seriesOther
In one 63-year-old woman with obesity receiving liraglutide alongside lifestyle modification, benign Alport carrier work-up permitted successful kidney donation; no isolated drug effect was established.
In plain wordsIn one woman with obesity receiving liraglutide and lifestyle care, successful kidney donation followed clinical work-up; an isolated drug effect was unproven.
Peptide
Liraglutide
Outcome
Not applicableSuccessful kidney donation after weight-management course
Study
n = 1
Outcome group
Overall treatment effect · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Despite hematuria, biopsy and genetic testing revealed a benign carrier condition of Alport syndrome, which, without proteinuria or renal impairment, allowed successful kidney donation.
3 context sentences(design, population, supporting numbers)
Summary · context
We are presenting the case of a 63-year-old woman with grade II obesity who was initially denied being a kidney donor to her son because of her weight.
Summary · context
Under these circumstances, she underwent comprehensive lifestyle modification in the cardio-obesitology clinic (caloric restriction, physical activity, and pharmacological treatment with liraglutide).
Summary · context
During the 3-month follow-up, she decreased her BMI to 33.4 kg/m², and subsequent examinations confirmed no surgical contraindications to donating a kidney.
Show in the study text Report a problemFND-4071087603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.